צמיחת הכנסות ב-12 חודשים נגררים: Jazz Pharmaceuticals Corp (JAZZ)

Jazz Pharmaceuticals dominates the narcolepsy and rare tumor treatment niche thanks to FDA protection. Xywav and Epidiolex are driving short-term momentum, as confirmed by the 12-month YoY sales dynamics on the GURU.Markets terminal chart, where the value 13.60 serves as the baseline indicator. Steady capital inflows and high profitability within the neurobiology segment guarantee business resilience.
jazzpharma.com (JAZZ) - פילוחי מדדים ודוחות פיננסיים

Jazz Pharmaceuticals revenues are based on the sale of high-cost drugs for the treatment of narcolepsy and epilepsy through government insurance funds. This trailing twelve-month (TTM) revenue chart allows for the real-time tracking of rolling revenue dynamics over four quarters. This metric measures the pace of business expansion, where local dips are often offset by internal cost optimization. For the long-term investor, this indicator serves as a signal of systemic shifts in the operating model.